New Data Shows Xanomeline-Trospium Combination Cuts Hospitalizations for Schizophrenia Patients
Real-world data presented in September 2026 shows that the drug combination of xanomeline and trospium reduces hospitalizations and lowers the burden of antipsychotic use in patients with schizophrenia. The findings add to growing evidence for muscarinic cholinergic therapies as an alternative to traditional antipsychotics. Psychiatric Times highlighted the data as part of its September focus on depressive disorders.
New real-world data shows that the combination of xanomeline and trospium reduces hospitalizations and decreases reliance on traditional antipsychotic medications in patients with schizophrenia, according to findings reported in September 2026.
The drug combination, marketed as KarXT, works through a different mechanism than most existing antipsychotics. Rather than targeting dopamine receptors, it acts on muscarinic cholinergic receptors in the brain. Researchers say this approach may offer benefits with a different side-effect profile than older medications.
The real-world data, highlighted by Psychiatric Times as part of its September 2026 focus on depressive disorders, showed that patients on the combination had fewer hospitalizations compared to those on standard antipsychotic regimens. Reduced hospitalization is a key measure of treatment effectiveness in schizophrenia, as hospitalizations are costly and disruptive for patients and families.
Bysanti, another medication targeting similar pathways, received approval in February 2026 for the treatment of schizophrenia and bipolar I disorder, adding to the options available to psychiatrists.
Schizophrenia affects approximately 24 million people worldwide. Traditional antipsychotics have been the standard of care for decades but carry significant side effects, including weight gain, metabolic changes, and movement disorders. The development of muscarinic therapies represents a shift in how researchers are approaching the condition.
Psychiatrists and researchers say the new data is promising but that longer-term studies are needed to fully understand the benefits and risks of xanomeline-trospium in broader patient populations.
